Cassava Sciences, Inc.

NasdaqCM:SAVA Stok Raporu

Piyasa değeri: US$184.7m

Cassava Sciences Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Cassava Sciences şirketinin toplam hissedar öz sermayesi $166.6M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $223.8M ve $57.1M dir.

Anahtar bilgiler

0%

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranın/a
NakitUS$148.98m
EşitlikUS$166.64m
Toplam yükümlülüklerUS$57.11m
Toplam varlıklarUS$223.75m

Son finansal sağlık güncellemeleri

Recent updates

Cassava Q3 Earnings Review: It Feels Like The End May Be Nigh

Nov 07

Cassava Sciences: Turning The Corner Into A Brick Wall

Jul 24

Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans

Oct 17
Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely

Jul 04
We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely

We're Not Very Worried About Cassava Sciences' (NASDAQ:SAVA) Cash Burn Rate

Mar 05
We're Not Very Worried About Cassava Sciences' (NASDAQ:SAVA) Cash Burn Rate

Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans

Nov 19
Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans

Cassava Sciences begins extension study of Alzheimer's drug simufilam

Oct 13

Cassava Sciences Stock: Huge Returns Or Catastrophic Losses

Sep 29

Cassava Sciences: Trying To Manage Expectations

Sep 21

Cassava Sciences reaches over five-month high on rising volumes

Sep 09

Cassava Sciences Looks As Good Of A Purchase As Ever

Sep 03

Cassava Sciences stock jumps 10% after director buys $860K shares

Aug 26

Cassava Sciences rally continues as stock up 39%

Aug 17

Cassava's Simufilam And Acetylcholinesterase Inhibitors: Similar Results

Aug 11

Cassava Sciences GAAP EPS of -$0.48 misses by $0.06

Aug 03

We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely

Aug 03
We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely

Cassava Sciences sheds 44% on report of criminal probe linked to Alzheimer’s drug

Jul 27

Cassava Sciences And Alzheimer's Disease: A Precipitious Path

Jun 10

Cassava Sciences: 3 Upcoming Catalysts That Could Decide Bull / Bear Debate

May 31

Cassava Sciences (NASDAQ:SAVA) has More Than Enough Funding to Function Until the Approval Process is Finished, but Investors may Need to be Ready for a Long Wait

Apr 19
Cassava Sciences (NASDAQ:SAVA) has More Than Enough Funding to Function Until the Approval Process is Finished, but Investors may Need to be Ready for a Long Wait

3 Key Points To Remember About Cassava Sciences

Apr 07

Retractions Of A Key Collaborator's Papers Set Up A Big April For Cassava Sciences

Mar 31

Cassava Sciences: Why The Stock Is Rangebound

Feb 28

The FDA Deals Another Blow To Cassava Sciences' Bears

Feb 11

Cassava Sciences, Inc.: Recent Trading Activity Presents An Opportunity

Feb 02

INmune Bio, The Biotech In My Stable For After Cassava Sciences

Jan 17

Cassava Sciences, Inc. - The Short Squeeze Has Started

Jan 06

Cassava Sciences, Inc. - A Rational Expectation If All Goes Well With Simufilam

Dec 30

Companies Like Cassava Sciences (NASDAQ:SAVA) Are In A Position To Invest In Growth

Dec 28
Companies Like Cassava Sciences (NASDAQ:SAVA) Are In A Position To Invest In Growth

Cassava Sciences Stock: Here We Go Again

Dec 21

Cassava Sciences Teaches Us 4 Lessons To Find The Next Big Thing

Dec 02

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: SAVA 'nin kısa vadeli varlıkları ( $202.5M ) kısa vadeli yükümlülüklerini ( $57.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: SAVA şirketinin kısa vadeli varlıkları ( $202.5M ) uzun vadeli yükümlülüklerini ( $80.0K ) aşmaktadır.


Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: SAVA borçsuzdur.

Borcun Azaltılması: SAVA son 5 yıldır borcu bulunmamaktadır.


Bilanço


Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: SAVA şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: SAVA serbest nakit akışı her yıl % 44.6 1.8 yıl yetecek nakit akışına sahip olacaktır.


Sağlıklı şirketleri keşfedin